Drug
CTS-1027
CTS-1027 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 75.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
75.0%
Based on 3 completed trials
Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
100%(3 trials)
Terminated
1(25%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
75.0%
3 of 4 finished
Non-Completion Rate
25.0%
1 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Terminated(1)
Detailed Status
Completed3
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
terminated125%
completed375%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
NCT01273064
completedphase_2
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
NCT01051921
completedphase_2
CTS-1027 in Interferon-Naive Hepatitis C Patients
NCT00925990
completedphase_2
Study of CTS-1027 in Hepatitis C Patients
NCT00570336
Clinical Trials (4)
Showing 4 of 4 trials
NCT01273064Phase 2
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
NCT01051921Phase 2
Study of CTS-1027 in Combination With Pegylated Interferon and Ribavirin in Hepatitis C Virus (HCV) Null-Responders
NCT00925990Phase 2
CTS-1027 in Interferon-Naive Hepatitis C Patients
NCT00570336Phase 2
Study of CTS-1027 in Hepatitis C Patients
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4